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Abstract: Schizophrenia (SCZ) and bipolar disorder (BIP) are severe mental disorders with a consid-
erable disease burden worldwide due to early age of onset, chronicity, and lack of efficient treatments
or prevention strategies. Whilst our current knowledge is that SCZ and BIP are highly heritable and
share common pathophysiological mechanisms associated with cellular signaling, neurotransmission,
energy metabolism, and neuroinflammation, the development of novel therapies has been hampered
by the unavailability of appropriate models to identify novel targetable pathomechanisms. Recent
data suggest that neuron–glia interactions are disturbed in SCZ and BIP, and are modulated by
estrogen (E2). However, most of the knowledge we have so far on the neuromodulatory effects
of E2 came from studies on animal models and human cell lines, and may not accurately reflect
many processes occurring exclusively in the human brain. Thus, here we highlight the advantages
of using induced pluripotent stem cell (iPSC) models to revisit studies of mechanisms underlying
beneficial effects of E2 in human brain cells. A better understanding of these mechanisms opens the
opportunity to identify putative targets of novel therapeutic agents for SCZ and BIP. In this review,
we first summarize the literature on the molecular mechanisms involved in SCZ and BIP pathology
and the beneficial effects of E2 on neuron–glia interactions. Then, we briefly present the most recent
developments in the iPSC field, emphasizing the potential of using patient-derived iPSCs as more
relevant models to study the effects of E2 on neuron–glia interactions.
Keywords: schizophrenia; bipolar disorder; estrogen; neuron–glia interactions; iPS cells; brain
organoids; drug target; pathophysiological mechanisms; in vitro model
1. Introduction
Mental disorders are debilitating complex diseases, characterized by highly heteroge-
neous alterations in mood and behavioral traits, usually arising early in life in affected indi-
viduals [1,2]. The etiology of these disorders is complex and remains largely unexplained,
hampering the development of preventive or curative treatments [3]. Schizophrenia (SCZ)
predominantly affects perception, thoughts, and cognition, whereas bipolar disorder (BIP)
mainly affects mood; however, there is a large degree of overlap in clinical characteristics
and psychopharmacological treatment. Furthermore, subjects with SCZ and BIP have a
significantly shorter life expectancy (e.g., due to comorbid somatic disease, accidents, or
suicide). Thus, many patients remain chronically ill, making mental disorders one of the
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leading causes of the global burden of disease [4,5]. SCZ and BIP have a life time risk
around 1% and 2%, respectively [6–8]. During the last decades, population and family-
based genetic studies have demonstrated high heritability (60–80%) estimates for both
SCZ and BIP, implicating genetic factors in disease etiology [9], with a large degree of
overlapping genetic risk factors.
One common feature of both SCZ and BIP is the presence of sexual dimorphism with
regards to prevalence, age of onset, symptom severity, and response to drug treatments [10–12],
as well as life expectancy [8,11]. Men have nearly 40% higher risk of developing SCZ
than women [11,13]. There is also evidence that the prevalence of BIP type I is higher
in men, whereas BIP type II is more prevalent in women [14]. Male patients with BIP
usually present with earlier onset than female patients and are more prone to develop
mania, and comorbid substance abuse as compared to female patients with BIP, who have a
higher tendency to present with comorbid disorders of panic, eating, post-traumatic stress,
and borderline personality [15]. A recent and large population-based study from Sweden
suggests that the prediction accuracy of polygenic risk scores (PRS) is significantly lower
in female participants with SCZ, compared to males [16].
In women, there is an increased risk of cognitive decline and dementia after menopause,
a period of a drastic decrease of estradiol levels (17β-estradiol, E2) [12,17], suggesting that
E2 may act as a physiological neuroprotector factor against age-related neurodegenerative
disorders [12,18]. Conversely, the Y chromosome gene SRY may act as a potential risk factor
for neurological disturbances in men [12], and suppressing its expression has conferred
neuroprotection in animal and cellular models of neurodegeneration [19]. Regarding severe
mental disorders, women with SCZ tend to respond better to antipsychotic therapy as
compared to men (recently reviewed in Reference [20]). Moreover, in women affected with
SCZ, decreases in the severity of psychotic symptoms correspond to periods of increased
E2 levels during the hormonal cycle, and vice versa, suggesting a neuromodulatory role of
E2 [12]. These observations resulted in the estrogen hypothesis of SCZ, which states that
E2 may provide protection from the development of SCZ [11,21].
Combining E2 or selective estrogen receptor modulators (SERMs) with antipsychotics
or mood stabilizers have been successful therapeutic strategies against SCZ and BIP symp-
toms [11,22,23]. This underscores the importance of a more detailed understanding of
the mechanisms underlying the neuromodulatory effect of E2 in mental illnesses, which
remains largely unknown, and holds the potential for improved treatments for both male
and female patients with SCZ and BIP [24].
In this regard, there is increasing evidence that the mechanisms by which E2 mod-
ulates neuronal activity are highly dependent on glial cells, since both neurons and glia
express different types of E2 receptors (ERs), where E2 binds to its cognate receptors di-
rectly or indirectly and influences the function and fate of neurons through neuron–glia
interactions [25–27]. However, studying neuron–glia crosstalk in mental disorders is a
challenging task given the limitations of accessing human brain tissue and the difficulties
of translating the complexity of the human brain to animal and cell line models [28]. One
promising approach is the use of induced pluripotent stem cells (iPSCs), which can be
obtained by reprogramming somatic cells from patients [28]. IPSCs derived from SCZ
and BIP patients have been routinely generated and differentiated into disease relevant
cell types such as neural progenitor cells (NPCs) [29], astrocytes [30] and neurons [31].
IPSCs can also be grown into three-dimensional (3D) structures known as organoids, or
“mini-brains”, which resemble specific brain regions [32,33]. The advantage of this model
system is that it enables us to study both neuronal networks similar to those in the human
brain, as well as interactions between glia and neurons.
In this review, we first describe the specific ERs present in the human brain, and then
present an update of recent genetic findings in SCZ and BIP, with a particular focus on
results from genome-wide associations studies (GWASs). Next, we give a brief overview
of key molecular aspects related to the pathophysiology of SCZ and BIP, including brain
energy metabolism, neuroinflammation, and neurotransmission. Then, we discuss the
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involvement of E2 in these processes. Additionally, we briefly review the current state of
the art in iPSC-based technologies and indicate how these tools can be utilized to study
neuron–glia interactions and to elucidate mechanisms underlying the beneficial effects of
E2 in SCZ and BIP.
2. Estrogen and Estrogen Receptors in the Brain
The pool of E2 in the brain is maintained by E2 synthesized in the gonads, breasts and
also by local production, since the enzyme aromatase, which converts androgens into E2,
is present in the brain [34]. E2 acts through genomic and non-genomic mechanisms. ERs
can act as ligand-activated transcription factors by directly binding to estrogen response
elements (EREs) sequences through classical signaling mechanisms [35], enabling E2 to
produce a wide range of transcriptional changes in different tissues and cell types. Genomic
signaling is mediated by nuclear receptors in the cellular cytoplasm. In this case, activated
ERs take a longer time to translocate to the nucleus and cause transcriptional activation,
leading to a prolonged action. Non-genomic mechanisms result in a faster effect, since
E2 is mediated by ERs at the plasma membrane and acts through second messenger
cascades [36]. The most studied ERs are the ERα, encoded by the estrogen receptor 1 (ESR1)
gene, and the ERβ, encoded by the estrogen receptor 2 (ESR2) gene, both expressed in the
human brain. E2 has greater affinity for ERα than for ERβ [37]. Both ERs are present in
the human prefrontal and temporal cortex, where ERα is more abundant in the nucleus
and ERβ in the cytoplasm, but it seems that the ERβ is not present in the layer I of the
temporal cortex [38,39]. However, in the human brain, ERβ is the predominant ER type in
the hippocampus [39,40], and thalamus [41], whereas ERα predominates in the amygdala
and hypothalamus [42]. Nevertheless, the fact that ERβ is the predominant estrogen
receptor type in the adult brain of rats and humans [39], whilst in the adult mouse brain
ERα predominates in the hippocampus and is almost absent in the cerebral cortex and
cerebellum [43], indicates that there are species differences in the brain expression of ERs,
and caution should be taken in extrapolating results from animal models to humans.
In addition to the steroid hormone receptors ERα and ERβ, a G-protein-coupled
receptor superfamily member, which is synthesized in the endoplasmic reticulum and
denominated either GP30 or G-protein estrogen receptor (GPER), has been identified. Upon
interaction with E2, GPERs undergo conformational changes inducing the conversion of
guanosine triphosphate (GTP) to guanosine diphosphate (GDP) within its Gα subunit,
which results in intracellular production of cyclic adenosine monophosphate (cAMP)
and rapid estrogen-mediated actions. GPER is widely expressed in the central nervous
system (CNS), especially in the hypothalamic pituitary axis, hippocampus, and brain stem
autonomic nuclei [44]. Finally, researchers have identified a putative ER, denominated
ER-X, which is characterized by its equal binding affinity for both 17α- and 17β-estradiol,
contrary to ERα and ERβ, which have 100 times greater binding affinity for 17β-estradiol
than for 17α-estradiol. ER-X is found within the plasma membrane of cells from the
neocortex. ER-X is upregulated in the neocortex of a mouse model of brain ischemic injury,
and since ER-X expression is developmentally regulated in the brain, with peak expression
at postnatal days 7–10 and reduced levels with age in adult mice, it has been suggested to
play a role in early stages of brain development [45].
In patients with SCZ, susceptibility SNPs in one intron of the ESR1 gene have been
reported, and are associated with decreased mRNA expression of ERα in the frontal cor-
tex [46,47]. Decreased ERα expression has also been reported not only in the hippocampus
of individuals with SCZ [48], but also in the hippocampus of ovariectomized rats, where
this effect is prevented by E2 treatment [49], suggesting that, at least in the case of female
rats, decreased E2 levels could downregulate hippocampal ERα expression. In intact and
ovariectomized rats, almost all of the ERβ-positive cells in the brain cortex and hippocam-
pus co-localize with the protein parvalbumin (PV), characteristic of gamma-aminobutyric
acid (GABA)ergic inhibitory neurons, suggesting a physiological role of E2 in the mod-
ulation of memory and cognition by controlling the inhibitory tone in the mentioned
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brain regions [49]. This co-localization of ERβ with hippocampal GABAergic neurons may
explain, at least in part, the fact that hippocampal GABAergic neurons are more affected in
men than in women with SCZ [50] and the fact that, in general, women with SCZ experience
less cognitive problems than men [51], since these cells produce gamma-band oscillations
that are essential for cognitive functions [52]. GPER has been implicated in hippocampal
neuroprotection in a rat model of global ischemia. When the animals were treated with E2
or with the non-classical ER agonists diphenylacrylamide or G1, the CA1 region of the hip-
pocampus was protected, and neuroprotection was abrogated by an antisense knockdown
of GPER [44]. The activation of GPER has also been associated with increased levels of the
antiapoptotic proteins Akt and Erk 1/2, neuroprotective effects relevant for neurodegen-
erative diseases, mechanisms of energy control in hypothalamic neurons, modulation of
cholinergic function and cognitive performance in the basal forebrain, and seems to play a
role in anxiety and stress responses [44].
3. Genetics of Schizophrenia and Bipolar Disorder
Genetic factors contribute substantially to the pathomechanisms underlying both SCZ
and BIP. Twin studies have consistently found high heritability estimates for both disorders:
a meta-analysis of 12 published twin studies of SCZ found that the heritability was 81%
(95% CI: 73–90%) [53]. A more recent twin study, which is the largest to date, comprising
31,524 twin pairs, found a similarly high heritability (79%) [54]. Heritability estimates for
BIP are nearly as high as SCZ and range from 59 to 87% [55]. A recent population-based
twin study found the heritability of BIP to be 60.4% [56]. A Swedish family based study
found the heritability for SCZ and BIP was 64% and 59%, respectively [9].
The Psychiatric Genomics Consortium (PGC), a large international collaboration [57],
has provided large-scale GWAS data to decipher the genetic architecture underlying
SCZ [58] and BIP [59]. Several works from this consortium have identified strong as-
sociations between multiple common genetic variants of small effects and SCZ and BIP,
and have suggested that SCZ and BIP are neurodevelopmental disorders that not only
share clinical symptoms, but also display a substantial genetic overlap [9]. For a complete
review of the polygenic architecture of SCZ, see Reference [60].
A landmark GWAS by the PGC, using a sample of 36,989 cases and 113,075 controls,
identified 108 loci associated with an increased risk for SCZ, 75% of which include protein-
coding genes, many being expressed in the brain [61]. Recently, the PGC Working Group
on SCZ performed analysis on 69,369 SCZ patients and 236,642 controls and identified
common variant associations at 270 distinct loci [62]. Fine-mapped candidates were en-
riched for genes associated with rare disruptive coding variants in SCZ patients, including
the glutamate receptor subunit GRIN2A and the transcription factor SP4, as well as genes
implicated in autism and developmental disorder. Interestingly, there was a convergence
of common and rare variant associations in SCZ and neurodevelopmental disorders [62].
Other GWASs have identified a large number of susceptibility loci associated with
mental disorders, including 30 for BIP [59] and 44 for major depressive disorder [63]. Genes
located within the associated genomic regions are highly enriched for biological pathways
involved in neurodevelopment, cellular signaling and immunity, such as ion channel
signaling, synaptic function and neurotransmitter pathways [64–66]. Recently, a GWAS
including 41,917 BIP cases and 371,549 controls identified 64 associated genomic loci. These
BIP risk alleles were particularly enriched for genes expressed in neurons of the prefrontal
cortex and hippocampus involved in synaptic and calcium signaling pathways [67].
In the past five years, large transcriptomic datasets derived from multiple tissues,
cell lines, and organisms have been conducted and dysregulation of hundreds of genes in
different brain regions has been reported in SCZ [60,68–70]. Moreover, it has been shown
that patterns of transcriptional dysregulation are shared across major psychiatric disorders,
confirming a genetic overlap between psychiatric disorders also at the transcriptome
level [71].
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Additionally, a recent proteomic analysis review of postmortem brain tissue showed
alterations in 92 energy metabolism proteins in SCZ and in 95 energy metabolism proteins
in BIP. Of these proteins, 32 were shared between SCZ and BIP, and most of them related to
mitochondrial electron transport, response to reactive oxygen species and glycolysis [72].
Interestingly, immunological status, energy metabolism, and neurotransmission exert
strong influence on each other and are highly dependent on neuron–glia interactions [73].
GWASs from European descents [74] and from the Korean population [47] have
identified associations of SNPs related to E2 biosynthesis and ERs with SCZ. More recent
GWASs have identified that a genetic risk (E2 polygenic risk score) for higher plasma E2 is
negatively associated with hippocampal volume, but not with an increased risk of major
depressive disorder or postpartum depression [75]. However, the largest GWAS of anxiety
traits to date was able to identify genome-wide significant associations near genes involved
with the ERα (ESR1) [76]. Moreover, the SNP rs2144025 has been associated with increased
ESR1 mRNA levels in prefrontal cortex from subjects with BIP and SCZ and appears to
modulate traits in behavioral disorders [77].
4. Brain Energy Metabolism in Schizophrenia and Bipolar Disorder
4.1. Brain Energy Metabolism Overview
Despite the fact that the human brain accounts for only 2% of the body weight, it
expends around 20% of the total energy produced in the whole body [78]. This is due to
the high energy needs of neuronal cells for neurotransmission, including the formation
of action potentials, vesicular neurotransmitter transport and in the restoration of ion
gradients after neuronal depolarization by the Na+/K+-ATPase pump, in particular at
the presynaptic terminals [78,79]. The brain tissue relies highly on the adenosine triphos-
phate (ATP) produced via mitochondrial oxidative phosphorylation (OXPHOS) [78]. The
electron transport chain (ETC) is constituted of four enzyme complexes embedded in the
mitochondrial inner membrane (complexes I-IV), whose function is to transfer electrons
from energy substrates, such as glucose, pyruvate, and lactate, to the final electron acceptor,
oxygen. There is a concomitant transfer of protons (H+) into the mitochondrial matrix by
the complexes I, III and IV, generating a proton gradient that provides the energy necessary
for the phosphorylation of adenosine diphosphate (ADP) into ATP when the complex V
(ATP synthase) transports the protons from the mitochondrial matrix back to the mitochon-
drial intermembrane space. During the OXPHOS process, oxygen reactive species (ROS)
are formed as a byproduct of the mitochondrial respiration by the complexes I, II and III
of the ETC [80]. Besides acting as a cellular power plant to produce ATP, mitochondria
also act as important calcium (Ca2+) buffer for cells, regulating cellular oxidative stress,
and controlling cell fate and the synthesis of steroid hormones and growth factors in the
CNS [78].
The main source of energy for the brain under normal physiological conditions is
glucose, whilst lactate, triglycerides and ketone bodies can also be used under special
conditions [81]. Astrocytes have a predominantly glycolytic metabolism, producing ATP
from glucose under aerobic conditions and releasing lactate to the extracellular space.
Astrocytes are also able to use fatty acids as an energy source and to store glycogen [81,82].
Neuronal activity demands intense mitochondrial activity, along with accumulation of
neurotransmitters in the terminal synaptic cleft, especially glutamate, making neurons
highly susceptible to ROS damage and glutamate excitotoxicity [52]. This is the case for
PV GABAergic interneurons, fast spiking inhibitory neurons that produce large amounts
of ROS, which present a high expression of Ca2+ permeable AMPA receptors, and are
implicated in SCZ [52]. Since glucose is important to maintain the levels of glutathione,
an important ROS scavenger and precursor of glutamate, it has been postulated that,
contrary to astrocytes, neurons spare glucose as a neuroprotective strategy and preferably
use lactate as the main source of energy via OXPHOS [78]. Accordingly, since the 1990s the
astrocyte–neuron lactate shuttle (ANLS) hypothesis has postulated that in the presence of
high glutamate concentrations, astrocytes are stimulated to produce lactate from glucose
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and secrete it as a source of energy for neurons [78,83,84]. Despite being widely accepted,
there is some debate over the ANLS hypothesis since neurons are able to metabolize other
energy substrates than lactate [85,86].
4.2. Brain Energy Metabolism in SCZ and BIP
Proteomics studies in postmortem brain tissue have shown that SCZ and BIP share
common alterations in more than 30 proteins, most of them related to mitochondrial ETC
(complexes I and V), antioxidant defense (peroxiredoxins, glutathione S-transferase and
superoxide dismutase), glycolysis (pyruvate kinase and fosfofrutokinase), and ATP transfer
from the mitochondria to other cellular compartments (creatine kinase) [72]. This is in
agreement with several cellular and rodent models of SCZ and BIP finding associations
with mitochondrial malfunctioning and oxidative stress [87–93].
In addition, decreased levels of the subunit NDUFS7 of complex I have been found
in postmortem brain tissue from patients with BIP, suggesting an inhibition of complex
I activity, and increased protein carbonylation, a marker of oxidative stress [94]. A more
recent study used hippocampal-dentate-gyrus-like neurons derived from iPSCs of BIP
patients to model BIP. These cells had increased mitochondrial gene expression, increased
mitochondrial membrane potential, decreased mitochondrial size, and neuronal hyperex-
citability [31]. A study of postmortem brain tissue in patients with SCZ revealed a 43%
reduction in COX (ETC complex IV) activity in the cortex gyrus frontalis and a 63% reduc-
tion in the caudate nucleus [95]. Another study on postmortem brain from patients with
SCZ found decreased complex IV activity in the caudate nucleus but increased activity in
the putamen and nucleus accumbens of the brain, especially in patients that have suffered
from paranoia. However, the authors could not rule out the influence of neuroleptics treat-
ment on these effects [96]. Furthermore, a study investigating mitochondria isolated from
blood platelets from patients with SCZ, BIP and major depressive disorder showed a 240%
increase in complex I, but not in complex II activity, in SCZ patients compared to controls.
Interestingly, both medicated and non-medicated SCZ patients showed similar results [97].
Finally, a more recent study from Ni et al. (2019) tested mitochondrial function and gene
expression in iPSC-derived cortical interneurons (cINs) and glutamatergic neurons from
15 healthy controls and 15 patients with SCZ. Only SCZ cINs, but not SCZ glutamatergic
neurons, showed both decreased expression of mitochondrial genes and decreased mi-
tochondrial respiration. The genes ND2 and ND4L, implicated in the OXPHOS complex
I, were downregulated, and maximal respiration and reserve capacity were decreased.
Mitochondrial dysfunction was followed by an increase in ROS and reduced arborization,
only in the cINs, but not in the glutamatergic neurons, suggesting that mitochondrial
dysfunction is intrinsic to cortical interneurons in SCZ. Both the mitochondrial hypofunc-
tion and decreased arborization were reversed by treating cINs with acetyl-L-carnitine, a
well-known mitochondrial modulator, indicating that targeting mitochondrial dysfunction
in SCZ cINs may be utilized as a therapeutic intervention for certain clinical symptoms of
SCZ, such as alterations in gamma oscillations and cognition [98].
Interestingly, patients diagnosed with mitochondrial disorders often present with
psychiatric symptoms, and drugs used in the treatment of SCZ and BIP modulate mito-
chondrial metabolism [99,100]. Altogether, the aforementioned evidence strongly sug-
gests that mitochondrial metabolism and oxidative stress play an important role in the
pathophysiology of SCZ and BIP. Besides, there is evidence that mitophagy, the selective
elimination of malfunctioning mitochondria which is essential for maintaining cellular
viability, may be dysregulated in several psychiatric disorders [101]. In postmortembrains
of SCZ patients several key genes involved in neuronal autophagy were downregulated
and correlated with positive symptoms in SCZ [102]. In a microtubule-associated protein
6 (MAP6)-deficient mouse model of SCZ, the behavioral phenotype was ameliorated by
the administration of davunetide, a peptide which enhances autophagy. The symptoms
were completely rescued by a combination of davunetide and clozapine, indicating that
autophagy plays a role in SCZ [103]. In contrast, the impaired myelination followed by
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decreased oligodendrocyte densities and morphological alterations in these cells have been
attributed to increased oligodendrocyte autophagy in SCZ. Whilst a considerable amount
of oligodendrocyte-associated genes are downregulated in SCZ, DISC1 and PHB2, which
encode for mitophagy receptors at the inner mitochondrial membrane, are upregulated.
Moreover, the abrupt reduction in the number and densities of oligodendroglial mito-
chondria and the normal appearance of the remaining mitochondria point to an enhanced
mitophagy in oligodendrocytes in SCZ [104]. In patients with BIP, proteins related to
mitophagy in blood cells were downregulated, accompanied by decreased mitochondrial
ATP production and increased ROS levels [105]. Dysregulations of the mitophagic pathway
leads to the accumulation of damaged mitochondria, resulting in increased oxidative stress,
decreased mitochondrial Ca2+ buffering capacity and loss of ATP, which are particularly
harmful in post-mitotic cells such as neurons [105]. One could speculate that in BIP pa-
tients, the number of damaged mitochondria may exceed the capacity of mitophagy, and
apoptosis may become the dominant pathway to minimize tissue damage. In addition, a
cell non-autonomous cytoprotective mechanism, transcellular mitophagy, is able to me-
diate the removal of defective mitochondria, in which a pool of axonal mitochondria are
transported to and degraded by adjacent astrocytes. This process could be dysregulated
in SCZ and BIP [101]. Thus, it is conceivable that alterations in astrocytic transcellular
mitophagy could take place in SCZ and BIP. Interestingly, several antipsychotic drugs, such
as fluspirilene, trifluoperazine, and pimozide, and the mood stabilizer lithium are inducers
of autophagy [102,106], while haloperidol and clozapine block autophagy by inhibiting the
formation of autophagolysosomes [106].
Another important feature that is common to both SCZ and BIP is the presence of
an imbalance between proteins involved with the increase of intracellular Ca2+ and those
responsible for restoring Ca2+ levels [107]. Indeed, some antipsychotic drugs target either
the calmoduline pathway [108] or inositol-3-phosphate (IP3)-induced Ca2+ release [109].
In platelets of patients with BIP, thapsigargin, a drug that induces Ca2+ release from the
endoplasmic reticulum, elicits a greater Ca2+ release in patient platelets than in those from
controls [110], whereas platelets from patients with SCZ show increased cytosolic Ca2+
and calcium-related alterations in the distribution of membrane phospholipids [111]. This
is in line with the fact that among the most consistent GWAS findings are associations
between SNPs in the α1 subunit (CACNA1C) of the voltage-gated L-type Ca2+ channel
(LTCC) Cav1.2 and SCZ and BIP [112], and that several proteins related to Ca2+ metabolism
are found altered in individuals with SCZ [113]. These Ca2+ channel alterations may
impact mitochondrial metabolism, since modulating LTTC or the CACNA1C gene prevents
mitochondrial ROS overproduction, disruption of mitochondrial membrane potential,
loss of ATP, decrease in mitochondrial respiration, and oxidative cell death in neuronal
cells [114]. Besides producing ATP and ROS, and mediating the effects of glutamate and
of brain-derived neurotrophic factor (BDNF) on neural plasticity, mitochondria have a
key role in buffering calcium and regulating apoptosis [99]. Thus, even in the absence
of Ca2+ signaling-related SNPs, Ca2+ imbalance in SCZ and BIP could also result from a
downstream effect of dysfunctional mitochondria, since disturbed mitochondria might fail
in the task of buffering cytosolic Ca2+ [93].
4.3. Influence of Estrogen on the Mitochondrial Metabolism
E2 modulates mitochondria in several ways, including the expression of ETC com-
plexes and ATP synthesis, ROS production and antioxidant defenses, apoptotic signaling
pathways, and Ca2+ homeostasis in both physiological and pathological conditions. The
classical model of ovariectomized mice has been used to test the effects of physiological
concentrations of E2 or specific E2 receptors on brain mitochondrial activity. Findings
suggest that the stimulation of both ERα and ERβ leads to an increase in complex IV (COX)
activity and in the expression levels of nuclear genes encoding the COX-IV subunit. ERβ
activation also promotes the expression of the mitochondrial genes encoding the COX-I
subunit. Both ERs increase the expression of the antioxidant enzymes manganese super-
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oxide dismutase (MnSOD), peroxiredoxin V (PrdxV) and phospholipid hydroperoxide
glutathione peroxidase (PhGPx4), resulting in reduced lipoperoxidation, and both ERs also
stimulate the maximal mitochondrial capacity in neurons and glia [115]. The activation of
specific nuclear ERs by E2 alters mitochondrial metabolism by modulating the expression
of respiratory chain complexes and other mitochondria associated proteins. For example,
the ER isoform ERβ1, but not the isoforms ERβ2 and ERβ3, is associated with mitochon-
drial protection against oxidative stress and mitochondrial membrane permeability in
human lens epithelial cells [116]. E2 treatment has been associated with increased expres-
sion of the cytochrome c oxidase subunits II [117], III [118], and VII [119], with increased
activity of the enzyme cytochrome c oxidase (ETC complex IV) [118], and with the ATP
synthase (ETC complex V) [120]. These effects possibly result from a direct regulation of
mitochondrial transcription, provoking an increase of the mitochondrial content in the
cells, since E2 provokes an increase in the ratio of mitochondrial DNA (mtDNA) over
nuclear DNA (nuDNA) [120]. Another important target of E2 is the nuclear respiratory
factor 1 (NRF-1), a mediator of mitochondrial activity and stimulator of mitochondrial
biogenesis via ERα [121]. E2 is able to modify the morphology and structural integrity of
mitochondria [122], and to increase the transcription of proteins for mitochondrial fusion
and fission in both male and female astrocytes [123]. Since astrocytes are essential for the
nutrition of neurons, it is believed that sex differences of E2 mitochondrial modulation
in astrocytes may explain, at least in part, gender differences in several brain cellular
pathologies [122].
E2 promotes cell survival signaling by increasing Ca2+ influx through the mitochon-
drial calcium uniporter (MCU) by an ERα-dependent mechanism [124]. E2 also enhances
the expression of anti-apoptotic proteins such as B-cell lymphoma 2 (Bcl-2) [125] and
antioxidant proteins, such as thioredoxin, manganese superoxide dismutase [126], and
glutathione [127]. Bcl-2 family proteins regulate the import of cytosolic Ca2+ into the
mitochondria, contributing to cellular Ca2+ buffering, and preventing the activation of the
permeability transition pore by cytosolic Ca2+-overload. E2 also prevents caspase-3 activa-
tion and mitochondrial cytochrome c release in models of glutamatergic excitotoxicity [128].
The SERMs tamoxifen and raloxifene reduce oxidative stress by increasing the expression of
antioxidant defense enzymes [22]. The antioxidant effect of raloxifene includes regulation
of Bcl-2, catalase, superoxide dismutase, and glutathione peroxidase gene expression and
the level of reduced glutathione in the brain [22]. Additionally, raloxifene increases mRNA
expression of apurinic/apyrimidinic endonuclease/redox factor-1 suggesting that it may
protect against ROS-induced DNA damage [22]. Experiments in which primary cultured
astrocytes are first deprived of oxygen and glucose and then treated with selective ER
agonists suggest that the protective effects of estrogen on mitochondrial function, cellular
death, and ATP production are mediated by ERα activation [129]. More recently, studies
using neuronal and organotypic slice cultures from ERβ-knockout mice attributed E2
neuroprotection against glutamatergic excitotoxicity and oxygen glucose deprivation to
a mechanism mediated by ERβ, which is able to prevent the mitochondrial permeability
transition (MPT) and Ca2+ toxicity [130]. Taken together, the aforementioned works suggest
a number of ways by which E2 may improve mitochondrial activity in several regions of
the CNS. However, studies of modulatory mechanisms of E2 on mitochondria of human
brain cells are still lacking, but hold the potential to confirm many of the routes identified in
cell lines and rodent models. Such studies may also identify new mechanisms underlying
the beneficial effects of E2 in several neurological conditions where gender differences exist,
such as mental disorders.
5. Neuroinflammation in Schizophrenia and Bipolar Disorder
5.1. Neuroinflammation Overview
The complex interactions of the brain and immune system have been shown to be
involved in the development and organization of the CNS tissue microenvironments,
as well as in neuronal survival and cortical functions, such as higher-order cognitive
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processes in health and disease [131–133]. Dysregulation of the brain-immune axis can
bring about a variety of pathologies, and manifestations of these abnormalities are usually
dependent on the cellular and intracellular systems involved. Neuroinflammation is one of
the most prominent and well-studied physiological consequences of a dysfunctional CNS-
immune relationship, and the neuroinflammatory aspects of neuropsychiatric disorders
are an emerging topic in biomedical research [133–136]. Interestingly, sex may underlie
the neurodegenerative and inflammatory hallmarks of these disorders and recent reports
suggest the functional engagement of glial cells, especially microglia, in the process [137].
Moreover, new evidence shows that variation of the complement component 4 (C4)
genes C4A and C4B, which have been linked to increased risk for SCZ, contribute to sex-
biased vulnerability: C4 alleles act more strongly in men than in women, implicating
the complement system as a source of sexual dimorphism in vulnerability to SCZ [138].
Unlike SCZ, BIP appears to be less strongly characterized by gender-based pathophysio-
logical dissimilarities with regards to neuroinflammation. However, aberrant and chronic
inflammatory dysregulation of glial functions have also been documented in BIP [139].
This section aims to briefly summarize the causative role of different glial cells in
neuroinflammation and the inflammatory gliopathy aspects of SCZ and BIP, as well as to
discuss the possible influence of sex hormones and estrogen-related neuroendocrine and
immune effects on glial cell functions and neuron–glia crosstalk.
5.2. Immune Responses and Inflammatory Glial Functions in SCZ and BIP
The immune system is an evolutionally advanced defense mechanism whose main
role is to protect and conserve the integrity of the “biological self” from invading microbes
and different forms of endogenous malignancies. The two major branches of the immune
response are innate and adaptive immunity, which represent an ancient, germline-encoded,
non-specific, rapid, and an adaptive, slower and highly antigen-specific response mecha-
nism, respectively [140]. The secretion of inflammatory cytokines (e.g., interleukins, such
as IL-1β, IL-6, and tumor necrosis factor-alpha, TNF-α) in response to pathogenic stimuli
is an integrated part of the innate immune response, while the production of antibodies
and the generation of epitope-specific immune memory are largely based on the cells of
adaptive immunity [141]. Associations between SCZ, inflammation, and immune system
activity were first reported by multiple studies, and later supported by epidemiological
data suggesting an intricate causal connection between maternal infections, systemic in-
flammation, and altered cognitive functioning [142–146]. Early childhood autoimmune
conditions have been associated with increased likelihood of psychotic episodes and SCZ
in adults [147]. In addition, overall lifelong SCZ risk shows a strong positive correlation
with the number of severe infections in people with autoimmune background [147]. The ob-
served comorbidity tendencies between SCZ, infections and autoimmune disorders suggest
a common underlying inflammatory component and have been hypothesized to involve
the immunocompetent cells of the human brain: microglia and astrocytes [30,133,148].
Although microglia and macrophages are functionally similar and part of the mononu-
clear phagocyte system, macrophages derive from the myeloid–macrophage lineage whereas
microglia derives from the “primitive” or “primordial” c-KitloCD41lo erythroid progenitors
in the yolk sac [149–151]. The ramified microglia niche of the adult brain expresses typical
markers, such as CD11b, the fractalkine receptor CX3CR1, and the ionized calcium-binding
adapter molecule 1 (Iba1) [152]. They are strongly involved in CNS immuno-surveillance, as
well as in the neuroinflammatory processes of various neuropsychiatric disorders [151,153].
Neuroinflammation is characterized by region-specific activated microglia that upregulate
the expression of the translocator protein (TSPO). Several neuroimaging studies using
TSPO ligand reported neuroinflammation in both recent-onset SCZ [154] and in acute
SCZ-related psychosis [155]. These studies also suggest that microglia-related neuroinflam-
mation may be responsible for cortical and hippocampal atrophy, and cognitive decline in
SCZ. An alternative explanation also involves activated astrocytes that likewise express
TSPO, and that have also been documented in SCZ [133]. An interesting cell-type-intrinsic
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property of microglia is that an already primed (i.e., previously activated) glial cell can
respond to new stimuli in a much stronger and rapid manner [156]. They may also form
an immune memory of neuropathologies that can consecutively raise their responsiveness
to new inflammatory insults [157]. This may partly support the developmental hypoth-
esis of SCZ, as early (perinatal and/or childhood) infections and systemic inflammation
might pose a stimulatory effect on microglia increasing glial activation and psychosis risk
following later infections in adulthood.
The involvement of microglia-driven inflammation in the neuropathology of BIP was
first characterized by human positron emission tomography (PET), where the authors
described significantly increased in vivo microglia activity and consequent neuroinflam-
mation in the hippocampus of BIP patients relative to healthy individuals [158]. In a
follow-up study, the same group found a causal connection between increased microglial
activity and neuronal damage in the affected brain regions in BIP [159]. Besides microglia,
the oligodendrocyte compartment of the brain has also displayed abnormalities, such as
decreased myelination of axons and significantly reduced cell numbers in postmortem-
brain samples from individuals with BIP [160,161]. In line with this, studies have reported
strongly downregulated mRNA levels of oligodendrocyte-specific markers accompanied
by mitochondrial and inflammatory dysregulation in BIP, raising the possibility of im-
paired axonal myelination, maintenance and repair in the brain of patients (reviewed in
Reference [162]). It is important to note that chronic cellular stress in oligodendrocytes has
been linked to the release of microglia-activating cytokines and chemokines that may lead
to uncontrolled neuroinflammation [163], a process that has been suggested to play a role
in neurobehavioral changes in BIP [139]. In addition, recent hypotheses on the alteration
of peripheral immune functions and immune–glia crosstalk involve early T lymphocyte
defects in BIP, suggesting that the disorder shares a similar neuro-immune signature with
major depressive disorder (MDD) [164]. Mounting evidence shows that BIP pathophysiol-
ogy may include early abnormalities in monocyte and T lymphocyte networks, similarly to
those seen in MDD, which, however, can become in part restored with older age [139,165].
Furthermore, like SCZ and MDD, BIP shows significant comorbidity with systemic au-
toimmune pathologies, in which patients with existing autoimmune disorder(s) have an
increased risk of developing BIP later in life, supporting the immune-brain inflammatory
link in the etiology of the disease [166,167].
Astrocytes are characteristic neurosupportive glial cells of the CNS that also mediate
inflammatory and immune functions [168,169]. Recent reports in astrocyte in vitro and
in vivo experimental models, as well as in human postmortem brain samples, demonstrate
considerable alterations in neuropsychiatric disorders, such as decreased astrocyte-specific
functions and gene-signatures in major depression and anxiety, and increased neuroin-
flammation in SCZ [170]. Moreover, aberrant inflammatory astroglia functions have also
been linked to prefrontal cortex atrophy and cognitive impairment in SCZ [171]. Resident
glia-related neuroinflammation can be a consequence of dysregulated inflammasome acti-
vation. Inflammasomes are important elements of the innate immune system representing
the early phase of response against pathogens by the release of the pro-inflammatory
cytokines IL-1β and IL-18 via caspase 1 activation [172–174]. Recent studies demonstrated
that the elevation of serum and postmortem brain IL-1β levels is associated with symptom
severity and disease evolution in SCZ [175,176]. These inflammatory cytokines are essen-
tial in the activation of multiple downstream immune-effector pathways, and have also
been associated with SCZ pathophysiology via their hypothetically aberrant secretion by
glial cells [133]. Interestingly, multiple aspects of this innate immune activation and glia-
mediated neuroinflammation exhibit gender differences at both the cellular and systemic
levels [177,178].
5.3. The Effect of Sex Hormones on the Inflammatory Responses of Glial Cells: What Do We Know
so Far?
Due to the observed sex differences in the prevalence of inflammatory pathologies,
and the considerable variation in sensitivity in inflammation-related degenerative disorders
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across the lifespan, recent research efforts focus on sex differences in immune responses,
neuroinflammation, and neuronal cell death pathway signaling [178–182]. Sex hormones
influence neuronal death pathways, the neurotrophic activity of glial cells, and can also
modulate the immune system at multiple levels. Various lymphoid (e.g., T cells, B cells,
and natural killer cells) and myeloid cells (e.g., monocytes and macrophages), as well
as microglia and astrocytes express ERs [183,184]. It is important to note that the effect
of sex hormones on immune modulation can be dose-dependent. E2 has recently been
shown to increase the immunoreactivity of microglia to inflammatory cues in the peripu-
bertal sensitive period of female mice [185]. The authors showed that microglia in the
ventromedial hypothalamus displayed greatly increased inflammatory cytokine responses,
and acquired immunoreactive morphological features in the presence of E2 following
lipopolysaccharide (LPS) challenge [185]. For instance, low doses of E2 favor Th1 (inflam-
matory) responses while high doses induce Th2 (anti-inflammatory) skewing in CD4+
helper T cell differentiation [149,181]. Unlike E2, progesterone uniformly downregulates
the production of TNF-α and other inflammatory cytokines by exerting a direct inhibitory
effect on the key transcription factor nuclear factor kappa (BNf-κB) [186,187]. Progesterone
also modulates neurotransmission and oligodendrocyte and microglia activation, and thus
promotes neurorestorative functions (e.g., myelin repair) [183,188]. Androgens, on the
other hand, can both decrease and exacerbate neuroinflammation and related neuropatholo-
gies [189]. These data suggest that an underlying physiological sexual dimorphism exists at
the level of the regulation of inflammation and immune functions, however, the biological
foundations of this phenomenon are yet to be clarified.
Sexual differences in glial functions affect ion channel regulation, apoptotic signaling
cascades and autophagy, activation of microglia, neuron–glia responses to chemical and
physical insults (e.g., changes in ionic balance), and mitochondrial toxicity [178,190]. In-
terestingly, microglia present gender-based differences in cell numbers, brain distribution,
and cellular functions. For example, microglia isolated from female mice possess higher
expression of IL-4 and IL-10 receptors, and exhibit elevated production of IL-4, after IL-10
cytokine treatment relative to those isolated from male animals [149]. Conversely, microglia
from male mice have higher expression of Iba1 at sites of immune activation, and resting
glia have increased Neuroglobin and arginase-1 levels in males as compared to female
mice [149]. These sex differences have been hypothesized to be definitive in the increased
male vulnerability in SCZ. This may be in part because microglia and their inflammatory
and “neurosculpting” functions are involved in the developmental process of sexual differ-
entiation [191], and also due to the increased number of activated microglia in the male
brain under normal developmental circumstances [192,193]. In support of this idea, a recent
study found significant differences in the distribution, arborization, cellular stress profile,
and synaptic modulatory capacity of microglia in the hippocampus of male versus female
mouse offspring following innate immune activation (inflammatory challenge) [194]. The
same group also detected increased expression of inflammatory pathway genes in the
cerebral cortex and hippocampus of male mice challenged with the same innate immune
trigger [194]. Overall, these results suggest that the increased incidence of SCZ in males
might involve increased and dysregulated microglial responses to prenatal immune insults.
Aberrant microglial functions may also involve abnormal regulation of synaptic pruning,
neuron–glia crosstalk, neuroinflammation, oxidative stress, and autophagy, which may con-
tribute to the spectrum of cognitive impairments in SCZ in both sexes. Available literature
data on biological sex-related differences in neuroinflammation in BIP are scarce. However,
in the light of the presented reports regarding sexual dimorphism in inflammatory glial
functions in SCZ, results warrant further investigation into other psychotic disorders as
well.
6. Neurotransmission in Schizophrenia and Bipolar Disorder
Neurotransmitters are the chemicals responsible for controlling brain functions; they
exert this action by carrying, boosting, and balancing signals between neurons. Dys-
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functions in neurotransmission systems—including neurotransmitters, their receptors,
transporters, and all intracellular processes coupled to the activation of receptors for neu-
rotransmitters and growth factors—lead to deficits in neuronal transmission at chemical
synapses with severe consequences on brain processes and cognitive functions. Mounting
evidence [27,93,195–198] indicates that an imbalance of major excitatory and inhibitory neu-
rotransmitter systems in the brain (dopamine, serotonin, glutamate and GABA) underlies
the cognitive deficits and symptoms observed in both SCZ and BIP patients.
This section summarizes the main neurochemical hypotheses of SCZ and BIP and
highlights the most recent studies in support of these theories. In addition, it reviews the
role of astrocytes in neurotransmission and their functional deficits in psychotic disorders.
Finally, it provides an overview of the most recent findings on the critical role of sex
hormones in balancing the excitatory and inhibitory transmission pathways with rescue
properties on brain functions.
6.1. Altered Neurotransmission Pathways in SCZ and BIP
6.1.1. The Monoamine Theory
The monoamine hypothesis of SCZ and mood disorders postulates that an imbal-
ance in monoaminergic neurotransmission in the CNS is causally related to the clinical
features of SCZ and BIP [199–201]. Evidence suggests that dopamine levels are elevated
in certain areas of the brain, resulting in over-stimulation and excess sensory informa-
tion that correlates with difficulties in concentration, thought process, reality orientation,
feelings, and behavior [202,203]. In BIP, pharmacological evidence indicates that, mainly
due to the altered availability of dopamine D2/3 receptors and transporters [204], in-
trinsic dysregulation in the homoeostatic modulation of dopaminergic function would
increase dopaminergic transmission in mania and the converse would happen in depres-
sion [205–207]. In SCZ, the dopaminergic hypothesis is supported by the effectiveness of
all known antipsychotic drugs in alleviating the positive symptoms of SCZ by blocking
striatal dopamine D2 receptors [202,203,208]. More recent studies based on genetic animal
models with dysregulated dopaminergic neurotransmission [209] and pharmacological
approaches in patients have demonstrated hyperexcitability and deficits in sensory gating
that overlap with the behavioral deficits of SCZ and BIP patients [210].
Recent evidence suggests that abnormalities in serotonin activity also play an impor-
tant role in psychiatric disorders [198,211]. Postmortem studies indicate altered binding
density of serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT2A and abnormal levels of
5-hydroxyindoleacetic acid (5HIAA) and its precursor tryptophan [212–214]. Abnormal
expression of several noradrenaline (NE)- and 5-HT-related genes have been also found in
BIP patients [215]. These alterations have been implicated in the disruption of glutamate
signaling which leads to decreased action potential generation, hypometabolism, synaptic
atrophy, and grey matter loss [212].
6.1.2. The Glutamatergic and the GABAergic Hypotheses
More recent models hypothesize that a dysregulation of glutamatergic and GABAer-
gic neurotransmission have a primary role in the pathophysiology of SCZ [27,210] and
BIP [216,217], where dopaminergic imbalance would be a secondary effect [218].
In the CNS, glutamate is the principal excitatory neurotransmitter and mediates the
fast-excitatory transmission by activation of the ionotropic glutamate receptors alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate, and N-methyl-
D-aspartate receptors (NMDARs), as well as metabotropic glutamate receptors (mGluRs).
The dominant glutamatergic hypothesis of SCZ postulates that psychotic symptoms and
cognitive impairments are due to a hypofunction of NMDARs, which leads to excessive
glutamate release and hyper-glutamatergic functions. In support of this theory, NMDAR
antagonists, like phencyclidine (PCP) and ketamine, produce negative symptoms and
cognitive dysfunction closely resembling SCZ phenotypes in healthy subjects [219–221].
In animal models, suppression of NMDAR function by pharmacological or genetic ap-
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proaches led to SCZ-like behaviors [222]. NMDAR hypofunction reduces the function of
GABAergic interneurons [223], which then leads to increased pyramidal cell firing due to
disinhibition [224] and increased downstream glutamatergic activity resulting in excitotox-
icity and cell death [225]. Glutamate dysregulation also causes dysregulation of cortical
dopamine [225,226] and contributes to disrupted GABAergic neurotransmission in the
brain [227,228].
GABA is the predominant inhibitory neurotransmitter in the CNS. It is synthesized
from glutamate by the enzyme glutamate decarboxylase (GAD). Studies using postmortem-
brain tissue from SCZ patients and animal models have indicated a deficiency of GABA
synthesis resulting from reduced transcription of GAD67 within PV-immunoreactive cor-
tical neurons, as well as a reduction in the subpopulation of GABAergic interneurons
positive for PV [227,229–233]. Additionally, several studies have indicated that glutamate-
mediated disruption of fast-spiking PV GABAergic interneuron pathways play a major role
in the generation of synchronicity and gamma oscillation in the brain. Subjects with SCZ
exhibit altered gamma-band activity that often correlates with symptoms and cognitive
deficit, suggesting that GABAergic transmission and PV interneurons are responsible for
the cognitive decline in SCZ [27,234,235].
Considerable evidence also implicates imbalanced glutamate and GABA neurotrans-
mission in the biochemical pathophysiology of BIP. In support of this, lithium, the first-line
treatment for mood stabilization in patients with BIP, reduces neuronal excitation by reduc-
ing dopamine levels, downregulating NMDAR-mediated release of glutamate, increasing
GABAergic neurotransmission and attenuating calcium metabolism and signaling in the
brain [236–239].
6.2. The Role of Astrocytes in Neurotransmission
Astrocytes regulate neurotransmission by altering the concentration of transmitters
both inside and outside the synaptic gap. Astrocytes are the primary locus for the biosyn-
thesis of glutamate from glucose, and regulate glutamate metabolism, transport, uptake,
and transmission [240]. In psychiatric disorders, the activity of glutamine synthetase (GS)
is reduced; this builds up intracellular glutamate in astrocytes, leading to reduced uptake
capacities of excitatory amino acid transporters (EAATs). It also reduces the production
of glutamine by astrocytic GS which is one of the major sources for maintaining synaptic
vesicle content of GABA in inhibitory interneurons. Decreases in GS expression levels,
loss of interneurons and deficient cortical GABA synthesis result in increased network
hyperexcitability and produce spontaneous recurrent seizures [241]. Deficits in EAAT
functions cause persistently increased glutamate levels in the brains of SCZ patients and
can increase the susceptibility of the brain to injury and cell death. Finally, astrocytes
influence NMDARs via D-serine, an agonist of the glycine-binding site of NMDA receptors,
and kynurenic acid (KYNA), an endogenous antagonist [148]. Therefore, an impairment in
the synthesis and accumulation of D-serine may lead to disrupted NMDAR activity and
cognitive deficits in SCZ [240].
Activation of astrocytes in SCZ patients [148] can trigger the excessive release of pro-
inflammatory agents (cytokines, interleukins, and chemokines) which damages neurons,
causes alteration of oligodendrocytes [242], and inhibits GABAergic interneurons [243].
Morphological changes of astrocytes can alter neuronal networks contributing to the
development of SCZ symptoms. Finally, in SCZ, glia lose the ability to form essential
components of the extracellular matrix with serious consequences for the stabilization and
maturation of synapses and neuronal connections, and the balance of neurotransmitter
systems [148].
6.3. The Effect of Estrogen on Neurotransmission
Mounting evidence indicates that E2 exerts profound effects on brain functions by
acting on the pathways of several neurotransmitters [26,48]. In particular, E2 has been
shown to be a potent neuromodulator, having positive effects on cognitive processes,
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including learning and memory, as well as mood [244]. The beneficial effects of E2 in
SCZ and BIP were proposed to occur through the modulation of monoamine transmitter
systems such as dopamine and serotonin [245–247].
E2 has been reported to have potent serotonin-modulating properties including the
regulation of the level of neurotransmitter synthesis, the degradation of 5-HT and the
density and binding of 5-HT receptors [248]. Recent findings suggest that E2 stimulates a
significant increase in the density of 5-HT2A binding sites in areas of the brain important for
the control of mood, mental state, cognition, emotion and behavior [245,249]. In support of
this, E2 therapy and 5-HT uptake blockers such as fluoxetine have proven good efficacy
in treating the depressive symptoms of the premenstrual syndrome. Interestingly, E2
treatment has been observed to decrease mRNA levels related to serotonergic neurotrans-
mission. For instance, E2 and progesterone treatment were shown to alter the expression
of several genes within the rat dorsal raphe nucleus that are involved in serotonergic trans-
mission, including the postsynaptic 5-HT2A receptor, the presynaptic SERT and vesicular
monoamine transporter (VMAT2) [246]. Additionally, the 5-HT1B autoreceptor mRNA
in the dorsal raphe [247] and the MAO-A mRNA and activity [250] are decreased after
estrogen treatment.
Sex hormones can also impact dopaminergic neurotransmission via a multitude of
mechanisms (synthesis, release, turnover and degradation, pre-and postsynaptic receptors,
transporters) that still require further investigation. Despite the conflicting findings, most
experts agree that E2 has an overall facilitating effect on dopaminergic neurotransmis-
sion [248]. In support of this theory, data indicate that E2 induces a substantial increase in
dopamine D2 receptors in the striatum [249]. In a different study, the protective action of
E2 in SCZ was mediated by downregulating the D2 receptor sensitivity, producing an effect
similar to that of antipsychotic drugs blocking DA neurotransmission. Both reduce the
probability of the occurrence of schizophrenic symptoms or the triggering of a psychotic
episode by enhancing the vulnerability threshold [246].
More recent findings indicate that the beneficial effects of E2 on cognitive functions
in SCZ and BIP patients also result from its effects on the glutamatergic and GABAergic
transmission systems [250]. E2 probably exerts its beneficial effects via the modulation of
glutamatergic synapses and neuronal excitability [244]. The impact of ovarian hormones on
the glutamatergic system has been studied extensively and both stimulatory and inhibitory
effects have been reported [248,251]. Whereas progesterone mainly impacts non-NMDA
receptors [251], the mechanisms underlying the effects of E2 on cognition are related
to NMDA glutamate receptors. E2 treatment promotes an increase in NMDA receptor
subunit expression, binding sites and neuronal sensitivity to synaptic input mediated
by NMDA glutamate receptors in the hippocampus [252,253]. Synaptic functioning and
neuronal excitability in the hippocampus are also subject to long-term and short-term
excitatory modulation by E2 [254]. An example comes from a work where E2 increased
spine density in the hippocampus and the number of excitatory synapses, where long-
term potentiation (LTP) can occur, leading to enhanced excitatory postsynaptic potentials
(EPSPs) and LTP [255–257]. E2 also facilitates the spine maturation process. A study has
shown that, in a cellular model of synapse loss relevant for SCZ and BIP, E2 can restore the
number of excitatory synapses [250]. Several other animal and in vitro studies have shown
that E2 may induce an increase in dendritic spine density through different mechanisms,
including the suppression of GABAergic inhibitory neurotransmission [258], as well as
the upregulation of AMPA [259,260] and NMDA receptors [252] in the hippocampus and
prefrontal cortex (PFC) [261].
With respect to the effect of hormones on the glutamatergic signaling pathway, E2
may protect against NMDA-mediated excitotoxicity [251], apoptosis [252] and oxidative
effects [254,255]. In addition to these cellular effects, the interaction between E2 and
glutamate can affect cognitive domains such as working memory and executive function
under harmful conditions [248].
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Sex hormones also interact with the GABAergic neurotransmission pathway. In
particular, E2 seems to suppress GABA inhibitory inputs [258]. Recent findings indicate that
E2 may alter the functioning of GABAergic and PV-expressing neurons by binding to ER-α
or ER-β [262], which then act as transcription factors to modulate the expression of PV [263]
and the synthesis of GABA, or to increase the number of postsynaptic GABAergic receptors
or their binding affinity. This would compensate for deficits of GAD67 and GABA synthesis
that represent typical phenotypes of SCZ and BIP [228]. E2 can also modulate the dynamics
of surface GABA receptors. Acute exposure of neurons to E2 leads to destabilization of the
specialized populations of GABAA receptors and the inhibitory scaffold protein gephyrin
at inhibitory synapses, leading to reductions in the efficacy of GABAergic inhibition via
a postsynaptic mechanism. Because this regulatory mechanism largely affects the fast-
synaptic inhibition in the adult brain, it may also have profound effects on the excitatory-
inhibitory balance which in turn influences synaptic plasticity and cognitive functions. It
is important to emphasize that virtually all the promising neuromodulatory effects of E2
described here have resulted from in vitro and in vivo studies using animal models or cell
lineages, which may not fully recapitulate the complexity of human brain circuitry. Human
disease models based on iPSCs are cutting edge technology that makes it possible to revisit
these important hypotheses on E2 neuromodulation in a more advanced disease model
(see more details on Section 8).
7. Transcriptional Effects of Estrogen
Given that the primary effect of ER activation is gene expression regulation, many
studies have investigated the complex and intricate transcriptional changes that are in-
duced by E2 binding to its receptors. The first global and hypothesis-free studies of E2
effects on gene expression were published almost two decades ago and relied on serial
analysis of gene expression (SAGE) and microarray technologies [264]. Although most of
these global experiments focused on the impact of E2 exposure in breast cancer cell lines,
they nevertheless revealed extensive regulatory effects of the hormone encompassing a
multitude of molecular pathways and mechanisms [265–269]. Interestingly, these studies
suggested that E2 downregulates many target genes that are either known to inhibit the
cell cycle or are pro-apoptotic, which is in agreement with the view that E2 promotes cell
survival and proliferation [264].
More recently, transcriptome-wide studies have also been carried out in CNS tissues
and cell types. One of the earliest of these studies investigated the transcriptional impact
of E2 in the primate prefrontal cortex and found that E2 significantly regulated 40 genes by
two-fold or more, including the neuronal activation marker c-FOS, which was increased
by 2.3-fold and localized specifically to pyramidal neurons [270]. Another study, which
examined the global effects of E2 and ER agonists in the rat frontal cortex, showed that
E2 had a significant impact on the expression of 16 genes, with an over-representation of
genes involved in neuroinflammatory processes [271]. These findings also indicated that
glial cells are potential targets of E2 action as several of the downregulated genes, such
as macrophage expressed-1 (MPEG1), CX3C chemokine receptor 1 (CX3CR1), cluster of
differentiation molecule 11b (CD11B), and toll-like receptor-4 (TLR4), are predominantly
expressed in microglia [271]. This suggests that E2 may suppress microglia reactivity and
thereby protect against inflammation-mediated neurotoxicity [271,272].
Both clinical and preclinical studies provide strong evidence that E2 has positive
effects on cognition [27,273], which is relevant to the cognitive dysfunction observed in
BIP and SCZ, since memory impairment is a core feature of these disorders [274]. This
has led many researchers to investigate the extent to which E2 treatment modulates gene
expression in the mammalian hippocampus. Aenlle et al. (2009) treated ovariectomized
mice with E2 for five weeks and performed microarray analysis on the hippocampal
tissue [275]. They found that 187 genes exhibited altered expression in response to E2.
This set of genes was enriched for functions that are critical for the growth and protection
of hippocampal cells, including transcription, cell signaling pathways, cell growth, and
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lipid and protein metabolism [275]. A similar study looked at global expression in the
mouse hippocampus after acute E2 exposure and identified 73 genes that were upregulated
and 53 that were downregulated, of which 17 and 6 genes are known to be involved in
learning and memory, respectively [276]. Several of these were validated with qPCR and
confirmed at the protein level, including the known E2 responsive heat shock protein gene
HSP70 and the synaptosome-specific gene SNAP25, which is required for neurotransmitter
release [276].
Widespread transcriptional effects of E2 have also been reported in cultured CNS cells.
Cultured neurons and glial cells obtained from the developing human brain and exposed
to E2 for seven days were found to alter the expression of 199 genes [277]. These genes
comprise several functional categories that are of interest with respect to the neuropro-
tective and neuromodulatory effects of E2 in the brain, such as cell differentiation, cell
cycle regulation, signal transduction, apoptosis, and ion channels and transporters [277],
indicating that both neurons and glial cells are important mediators of estrogen action.
In addition to the abovementioned global experiments, several studies have focused
on specific genes and pathways that have been associated with E2 through other lines of
evidence. These targeted studies have generally confirmed the associations of interest at
the transcriptional level, showing for example that E2 increases the mRNA expression
levels of BDNF [278,279], as well as several dopamine receptor subtypes in mammalian
brain tissues [280]. Moreover, E2 was found to upregulate the expression of catalytic
subunits of the mitochondrial respiratory chain complexes I, III, IV, and V in primary
astroglia, the major energy supplier in the CNS, providing further evidence that increased
ATP production and, in consequence, reduced ROS levels in astrocytes could represent a
mechanism by which E2 protects neurons from cell death under neurotoxic conditions [120].
Taken together, these global and targeted gene expression studies demonstrate that
E2 exerts complex transcriptional effects in the mammalian brain involving multiple
cellular processes and pathways. These processes could act as molecular mediators of the
neuroprotective effects attributed to E2 and its potential role in the development of CNS
disorders like SCZ and BIP. Although no study has yet investigated the specific effects of
E2 on neuron–glia interactions at the gene expression level, these findings do indicate that
both cell types are targeted by E2 and that it may protect neurons both directly and through
glial cell-mediated mechanisms. Table 1 displays a list of effects of E2 on mitochondrial
metabolism, inflammation, and neurotransmission which contribute to the neuroprotective
action of the hormone.
Table 1. List of studies addressing the effects of estrogen in different models.
Experimental Model Preparation E2 Effects Receptor Involved Reference
Ovariectomized mice Whole brain mitochondria
↑ activity of complex IV (COX); ↑
expression of nuDNA subunit COX
IV, mtDNA subunit COX I, and of
the antioxidant enzymes MnSOD,
PrdxV, and glutathione peroxidase; ↓
lipoperoxidation; ↑maximal
mitochondrial capacity
ERα or Erβ Irwin et al., 2012 [115]
Human lens cells Cell culture ↓ oxidative stress; ↓mitochondrialmembrane permeability ERβ1 Flynn et al., 2008 [116]
Human pituitary tumor cells Cell culture ↑ expression of the COX II subunit N.I. Van Itallie et al., 1988 [117]
Rats Hippocampal tissue ↑ expression of the COX III subunit;↑ activity of COX N.I. Bettini et al., 1992 [118]
Several human cell lines Cell culture ↑ expression of the COX VII subunit N.I. Watanabe et al., 1998 [119]
Mouse cortical and
mesencephalic astrocytes Cell culture
↑ expression of catalytic subunits of
the ETC complexes I, III, IV and V; ↑
activity of ATP synthase; ↑
mtDNA/nuDNA ratio
N.I. Araújo et al., 2008 [120]
MCF-7 and H1793 cells Cell culture ↑ expression of NRF-1; ↑mitochondrial biogenesis N.I. Mattingly et al., 2008 [121]
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Table 1. Cont.
Experimental Model Preparation E2 Effects Receptor Involved Reference
Mouse astrocytes Cell culture ↑ transcription of mitochondrialfusion/fission proteins N.I. Arnold et al., 2008 [123]
HeLa cells Cell culture ↑MCU-mediated mitochondrialCa2+ uptake N.I. Lobatón et al., 2005 [124]
Ischemia-perfusion in Female
rats Brain tissue
↑ expression of anti-apoptotic
proteins (e.g., Bcl-2) Erα Zhang et al., 2017 [125]









↓ apoptosis; prevention of
cytochrome c release; ↓ expression of
caspase-3
N.I. Zhang et al., 2005 [128]








Cell culture ↓ release of lactate dehydrogenase Classical estrogenreceptors Singer et al., 1996 [281]
Ovariectomized rats Hypothalamic arcuatenucleus





submitted to oxidative stress
inducers
Cell and organotypic culture Prevention of peroxide accumulation Independent on anyER activation Behl et al., 1997 [283]
Ovariectomized rats Several brain regions Prevention of serotonin-receptor lossdue to ovariectomy N.I. Cyr et al., 2000 [284]
Ovariectomized rats CA1-region hippocampalneurons
↑ excitability, independent of NMDA
receptors N.I. Wong et al., 1992 [254]
Male adult rats Hippocampal slices
↑ synaptic responses by a
mechanism dependent on integrin
activation and signaling
Erβ Wang et al., 2016 [257]
Rats and mice Cell culture and brain slices
↓ amplitude of inhibitory synaptic
currents; destabilization of
GABAARs and gephyrin at
inhibitory synapses
N.I. Mukherjee et al., 2017 [285]
Rats Frontal cortex organotypicslice cultures
↑ cortical expression of parvalbumin
in both deep and superficial layers N.I. Ross and Porter, 2002 [263]
Ovariectomized monkeys Dorsolateral prefrontal cortex
Regulated 40 genes, including ↑
expression of C-FOS and ↓
expression of E2F1 and TFIIB mRNA
and protein
N.I. Wang et al., 2004 [270]
Ovariectomized rats Frontal cortex
Regulated 16 genes including ↓
expression of complement C3 and
C4b, Ccl2, Tgfb1, macrophage
expressed gene Mpeg1, RT1-Aw2,
Cx3cr1, Fcgr2b, Cd11b, Tlr4 and Tlr9,
defensin Np4, RatNP-3b, IgG-2a, Il6
and the ER gene Esr1
ERα and Erβ Sárvári et al., 2011 [271]
Ovariectomized mice Hippocampus
Regulated 187 genes, mostly of them
involved in transcription, cell
signaling, cell growth, and lipid and
protein metabolism
N.I. Aenlle et al., 2009 [275]
Female mice Dorsal hippocampus
Alteration in the expression of 204
genes, of which 23 are involved with
learning/memory; changes in the
content of the proteins Hsp70,
Igfbp2, Actn4, Tubb2a, and Snap25
N.I. Pechenino and Frick,2009 [276]
Human fetus Neuron and glial cell cultures
Altered expression of 199 genes,
many implicated in cell
differentiation, cell cycle regulation,
signal transduction, apoptosis, and
ion channels and transporters
N.I. Csöregh et al., 2009 [277]




spinal cord ↑ expression of the BDNF gene N.I.





and ventral tegmental area
↑ levels of dopamine and serotonin
receptors mRNA; ↓ levels of ERα
and ERβ mRNA
N.I. Zhou et al., 2002 [280]
Human cells iPSC-derived forebrainneurons ↑ number of dendritic branches N.I. Shum et al., 2015 [286]




Activation of integrin α5β1 in the
rat striatum; ↑ integration of grafted
neurons into host striatum
N.I. Nishimura et al., 2016 [287]
↑, increased; ↓, decreased; ETC, electron transport chain; BDNF, brain-derived neurotrophic factor; iPSC, induced pluripotent stem cell;
LPS, lipopolysaccharide; MCU, mitochondrial calcium uniporter; N.I., not informed in the study; NMDA, N-methyl-D-aspartate.
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8. Induced Pluripotent Stem Cell (iPSC) Models to Study Neuron–Glia Interactions
The discovery of iPSCs [288] has offered new and promising prospects for studying
and treating complex diseases. Some of the main applications of iPSCs include the fields of
regenerative medicine, disease modeling, drug screening, toxicity assessments and clinical
cell therapies. Like any other cellular model, iPSCs also hold some limitations, like genetic
instability, tumorigenic threat after transplant, and lack of proper epigenetic resetting after
iPSC differentiation [289–291]. Nevertheless, iPSC-derived models still embody one of the
best platforms to study polygenic disorders such as SCZ and BIP, since animal models
cannot fully reproduce the complexity of polygenic disease phenotypes. In fact, during the
past years iPSCs have been demonstrated to be a useful tool as in vitro models to study
neurodegenerative disorders such as amyotrophic lateral sclerosis [292,293], Huntington’s
disease [294] or Alzheimer’s disease [295,296], and neurodevelopmental disorders like
SCZ [30,98,297] and BIP [31,298], among other diseases. IPSC technology can be useful
in the identification of specific genes involved in drug-response in highly heritable dis-
orders, such as SCZ and BIP, by comparing transcriptomic data of iPSC-neurons from
patients that are responsive to a specific drug treatment with data from those that are
non-responsive. Nakazawa and colleagues (2017) used this strategy by producing TUJ1+
neurons differentiated from iPSCs derived from a rare case of homozygotic twins with SCZ
in which one was responsive, and the other non-responsive to clozapine treatment. The
iPSC-neurons were treated with clozapine which resulted in different expression levels
of cell adhesion molecule genes, such as CDH8, DS3 and protocadherin genes, between
the responsive and non-responsive twin. Alterations in these molecules in the brain can
potentially result in dendritic and synaptic changes, resulting in alterations in the neural
circuitry and clinical symptoms [299]. Interestingly, one study presented preliminary data
about the beneficial role of E2 in iPSC-neurons, where they showed that treatment with
10 nM E2 for 24 h results in an increase in dendritic branching [286]. However, the iPSCs
were derived from only one healthy male individual, and no additional investigation
was done with iPSC-derived neurons from patients. In addition, it has been shown that
the systemic administration of estradiol-2-benzoate (E2B) into a rat model of Parkinson’s
disease facilitated the integration of grafted dopaminergic neurons derived from human
iPSC into the host neuronal circuit [287].
A further development within iPSC research was the establishment of cellular co-
culture models, allowing cell–cell interactions accurately mimicking the in vivo environ-
ment of astrocyte–neuron coordination [297,300–304]. However, one of the biggest issues
in human neuron–astrocyte co-culture research has been the usage of rodent astrocytes to-
gether with human iPSC derived neurons, which might be counterproductive due to known
differences between human and rodent glial gene expression [305–307]. Furthermore, try-
ing to recreate in vitro the astroglia–neuron interactions present in mental disorders like
SCZ and BIP with rodent astrocytes does not appear to be an ideal experimental setup,
given the differences between human and rodent brain cells. Astrocyte complexity greatly
increased during hominid evolution and species differences should be taken into account
when studying mechanisms underlying human neurological disorders [308–310]. In fact,
it has been proposed that human cortical evolution was accompanied by an increasing
complexity in the function and morphology of astrocytes, with an expansion of their roles
in synaptic modulation and cortical circuitry [309]. For example, in a recently published
study using a humanized glial chimeric mouse model, iPSC-derived glial progenitor cells
(GPC) from childhood-onset SCZ patients were implanted into myelin-deficient mice.
Interestingly, this resulted in compromised glial maturation with reduced white matter
expansion of the GPC, astrocytic differentiation delay and abnormal cellular morpholo-
gies [311]. Another work has established a human cortical iPSC system for investigating
astrocyte-to-neuron interactions. Cortical astrocytes and neurons were generated from a
common pool of OTX2+ cortical radial glia progenitors. The iPSC-astrocytes expressed
well-known astrocyte-specific genes, astrocyte-specific membrane properties, gap-junction
coupling, and showed capacity to respond to neurotransmitters such as glutamate and ATP.
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In such co-cultures the cortical iPSC-derived astrocytes accelerated the maturation of corti-
cal iPSC-derived neurons by increasing electrical excitability and synaptic network activity.
This was reinforced by the fact that the astrocytes expressed genes encoding extracellular
enzymes that promote synapse structure and maturation, glutamatergic transmission, cell
adhesion, neurite outgrowth, and synaptic development [312]. Thus, this model provides a
source of human astrocytes and neurons suitable for astrocyte–neuron signaling studies in
neurodevelopmental pathologies like SCZ and BIP.
Recently, the development of iPSC-derived 3D systems have raised great promise
in the field of in vitro brain disease modeling [32,313–318], where different strategies are
being used to generate brain organoids representing different regions analogous to the
midbrain [319], hindbrain [320,321] and forebrain [314,317,318], adding an extra layer
of complexity in comparison with 2D iPSC-derived models. However, limitations of
brain organoids include the lack of vascularization and a high variability between repli-
cates [32,314]. In addition, some of the neuronal population in 3D systems are not well
specified and contain a mixture of mature and progenitor cells, without a precise control
over cell maturity [314,317,318,322,323]. Nevertheless, some attempts have been made to
solve the lack of vascularization by transplanting the brain organoids into mice brains [324],
and to reduce variability using novel protocols [317,318]. Therefore, despite these limita-
tions, brain organoids still embody the best current models for the study of neuron–glia
interactions, since they recapitulate brain architecture and function. After long periods
of differentiation and maturation, they are able to innately develop astrocytes and mi-
croglia [317,318,325] and recreate complex oscillatory waves similar to the ones found in
the neonatal brain EEG signals [326]. Here we highlight the potential benefits of studying
the effects of E2 in neuron–glia interactions using in vitro models of BIP and SCZ based on
iPSCs derived from patients, whilst the advantages of using cerebral organoids to study the
influence of steroid hormones in brain development have been reviewed elsewhere [327].
The different cellular models based on iPSCs and their applicability for genetic, metabolic,
and electrophysiological studies are shown in the Figure 1.
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9. Conclusions and Perspectives
SCZ and BIP are severe mental disorders which are difficult to treat, causing life-long
morbidity in a large number of young individuals worldwide. SCZ and BIP share not only
clinical symptoms, but also genetic factors and pathophysiological mechanisms affecting
energy metabolism, immune status, neurotransmission, and neuron–glia interactions. As
these systems are interrelated and involved in crosstalk with one another, it is difficult to
identify alterations that are intrinsic, and appear first in the course of the disease, from
the ones that are secondary and appear later, as a result of primary alterations. Sexual
dimorphism seems to be present in both disorders, with women being, in general, less
affected than men, and evidence suggests that the female hormone E2 could be an im-
portant factor responsible for this difference. In fact, a number of studies have shown
neuroprotective effects of E2 upon different brain cell insults in several animal and cellular
models of disorders involving sexual dimorphism. Beneficial effects of E2 have been at-
tributed to its influence on energy metabolism, immune system, and neurotransmission, all
affected in SCZ and BIP. Indeed, E2 and SERMs have been successfully used as adjuvant
drugs in BIP and SCZ clinical trials, highlighting the importance of understanding the
precise mechanisms underlying beneficial effects of E2 in BIP and SCZ in order to identify
novel and sex-specific drug targets for SCZ and BIP. Indeed, meta-analyses of random-
ized controlled trials have shown that the SERM raloxifen is effective in improving total
symptom severity in SCZ spectrum disorders [328], as well as the Positive and Negative
Syndrome Scale (PANSS) total psychopathology, positive and negative symptoms, and
general psychopathology scores in postmenopausal women with SCZ [329]. Clinical trials
have also confirmed that the SERM tamoxifen has been effective to treat episodes of mania
in BIP patients [330]. Growing evidence has shown that besides autonomous effects of
E2 on neurons, the non-autonomous effects of E2 via glial cells, such as astrocytes and
microglia, are essential for E2 neuromodulatory effects. Disease models of BIP and SCZ
have gradually moved from rodents, human peripheral blood and postmortembrain tissue
into patient-derived iPSCs differentiated into brain cells and organoids, which offer several
advantages and avoid many of the limitations associated with other model systems. In
particular, when studying the mechanisms underlying E2 beneficial properties, one should
be cautious of extrapolating results from animals to humans due to interspecies differences
in the expression of the different ER types across different brain regions. In addition, since
the neuromodulatory role of E2 involve neuron–glia interactions, iPSC-derived cells and
3D cultures are better suited for this purpose. Different types of iPSC-derived neural cells
can grow as monocultures, mixed co-cultures, brain organoids, or specific brain region
spheroids and be treated with E2 before being tested for a number of parameters, including
gene expression, as well as parameters of energy metabolism, inflammation, and electro-
physiology. IPSC-based models are a relatively new technology that will continue to evolve
in terms of cellular composition and network, allowing the measurement of an increasing
number of parameters. In this context, testing the mechanisms underlying beneficial or cell-
damaging effects of sex hormones in SCZ and BIP, using an iPSC-based models, arises as a
promising new research field. Additionally, unveiling, in detail, the mechanisms by which
E2 displays beneficial effects to the CNS will lead to the identification of potential targets
for the development and discovery of new drugs to treat several neurological disorders.
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